Boston, MA 03/28/2014 (wallstreetpr) – For investors who want value, hunting for the most promising stocks is second nature. But sometimes you have so many options to consider that you can get overwhelmed. And this is why Nuvilex Inc (OTCMKTS:NVLX) takes the stage today. This company operates independently and also through subsidiaries which it owns wholly. Its line of products is development of treatment for cancer and diabetes. The company holds the worldwide right to live-cell encapsulation.
With growing excitement and opportunities in medical marijuana, the company has interest in the cannabis sectors, where it already has a business subsidiary.
Upcoming events and their impact
Talk about medical marijuana and Nuvilex Inc (OTCMKTS:NVLX) will be dispatching one of its executives to present at the upcoming medical cannabis unity conference in Washington, D.C. The company announced that Dr. Mark L. Rabe who is the current chair of the advisory board of its Medical Marijuana Sciences subsidiary will present at the April 5 – 7, event. Dr. Rabe, will issue a review of the history of medical use of cannabis and the constituents of pot which have biological values. Particular emphasis will be placed on the serious diseases which marijuana extracts can help in solving.
The company recently tapped Dr. Brian Salmons to the advisory board of its subsidiary, Medical Marijuana Sciences. All these are in efforts to ensure that top-notch brains and technologies are deployed to work in the promising medical cannabis industry, of course, with an eye on creating shareholder value.
Pancreatic cancer treatment
High on the agenda of Nuvilex Inc (OTCMKTS:NVLX)’s ongoing research and development activities is solving the riddles that are cancer and diabetes. And the company is making good of its global right to live-cell technology to bring to the market a ground breaking therapy for pancreatic cancer.
As the company takes its research and development of cancer therapies from success to success, investors are already flocking in with their dollars. And in a press release, the company recently announced receiving $27 million towards clinical trial of its pancreatic cancer drugs. The funds came from an institutional investors based in Chicago.
According to the company, with its drugs currently under clinical trials showing significant success, it is just a matter of time before they pull through with “gold standard” status, the kind that earned Eli Lilly and Co (NYSE:LLY) more than $10 million in milestone payments through its drug Gemzar.
They say that the best way to play biotech stock is to exercise patience because patients are needed. Anyway, investors who have been patient with the progress with Nuvilex Inc (OTCMKTS:NVLX) are not far from smiling all the way to the bank now that milestones payments are expected to start coming in torrent.
This entry passed through the Full-Text RSS service — if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.